Cilostazol enhances atorvastatin-induced vasodilation of female rat aorta during aging

dc.contributor.authorNurullahoglu-Atalik, K. E.
dc.contributor.authorKutlu, S.
dc.contributor.authorSolak, H.
dc.contributor.authorKoca, R. Ozen
dc.date.accessioned2024-02-23T14:32:05Z
dc.date.available2024-02-23T14:32:05Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractStatins have cholesterol-independent effects including an increased vascular nitric oxide activity and are commonly used by patients with cardiovascular disease. Such patients frequently have cardiovascular diseases, which may be treated with cilostazol, a platelet aggregation inhibitor. This study was designed to investigate whether combined use of cilostazol would increase the inhibitory effect of statin on vascular smooth muscle and how maturation would affect these responses. Female Wistar rats, aged 3-4 months (young) and 14-15 months (adult), were sacrificed by cervical dislocation and the thoracic aorta was dissected and cut into 3- to 4-mm-long rings. The rings were mounted under a resting tension of 1 g in a 20-ml organ bath filled with Krebs-Henseleit solution. Rings were precontracted with phenylephrine (10(-6) M), and the presence of endothelium was confirmed with acetylcholine (10(-6) M). Then, the concentration-response curves were obtained for atorvastatin alone (10(-10) to 3 x 10(-4) M; control) and in the presence of cilostazol (10(-6) M) in young and adult rat aortas. This experimental protocol was also carried out in aorta rings, which had been pretreated with NG-nitro-L-arginine methyl ester (L-NAME, 10(-4) M). Atorvastatin induced concentration-dependent relaxations in young and adult rat thoracic aorta rings precontracted with phenylephrine. The pIC(50) value of atorvastatin was significantly decreased in adult rat aortas. In addition, pretreatment of aortas with cilostazol enhanced the potency of atorvastatin in both young and adult aortas. Incubation with L-NAME did not completely eliminate the relaxations to atorvastatin in the presence of cilostazol. These results suggest that combined application of cilostazol with atorvastatin was significantly more potent than atorvastatin alone. Combined drug therapy may be efficacious in delaying the occurrence of cardiovascular events.en_US
dc.identifier.doi10.1556/2060.104.2017.3.3
dc.identifier.endpage234en_US
dc.identifier.issn2498-602X
dc.identifier.issue3en_US
dc.identifier.pmid28956637en_US
dc.identifier.scopus2-s2.0-85031508331en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage226en_US
dc.identifier.urihttps://doi.org/10.1556/2060.104.2017.3.3
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15484
dc.identifier.volume104en_US
dc.identifier.wosWOS:000411907600002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAkademiai Kiado Zrten_US
dc.relation.ispartofPhysiology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAgeen_US
dc.subjectAtorvastatinen_US
dc.subjectCilostazolen_US
dc.subjectRat Aortaen_US
dc.subjectNitric Oxideen_US
dc.subjectRelaxationen_US
dc.titleCilostazol enhances atorvastatin-induced vasodilation of female rat aorta during agingen_US
dc.typeArticleen_US

Dosyalar